Rezpegaldesleukin shows over 6-month off-treatment durability in alopecia areata
Nektar Therapeutics announced long-term data for rezpegaldesleukin at EADV 2026, showing durable hair regrowth after treatment cessation and initiation of Phase 3 studies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed